Home  /  Resource Library  /  Minimal Residual Disease Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing

Minimal Residual Disease Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing

Case report of patient treated with lorlatinib for treatment of refractory anaplastic large cell lymphoma.